Loading
Life sciences · Journal article
Infectious Diseases and Therapy · August 28, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a small retrospective single-centre case series describing eravacycline use in 8 patients with complex carbapenem-resistant infections, predominantly severe burns. Clinical cure was reported in 7 of 8 patients (87.5%) with no treatment-limiting adverse events, but the study provides no comparator group, formal statistical analysis, or powered assessment of efficacy or safety.
Retrospective single-centre case series. Patients treated at Hospital St. Georg in Leipzig, Germany with complex infections (bloodstream infections, hospital-acquired pneumonia, skin and soft tissue infections, osteomyelitis) caused by carbapenem-resistant pathogens. Underlying conditions included severe burns, multiple myeloma, and HIV i…. Intervention: Eravacycline 100 mg intravenous twice daily (monotherapy or combination regimens).. n = 8. Hospital St. Georg in Leipzig, Germany; a municipal tertiary care centre..
Clinical cure achieved in 87.5% of patients (7/8) Microbiological pathogen eradication in 7 of 8 patients, except one with major skin and soft tissue defects and osteomyelitis Median eravacycline treatment duration was 10 days (range 5–42 days)
Source does not report adverse event rates, detailed safety monitoring, or long-term follow-up beyond treatment duration. No adverse events leading to treatment discontinuation reported
This report provides preliminary observational evidence that eravacycline may be a tolerable option for treating carbapenem-resistant infections in real-world settings, particularly in burn and immunocompromised patients. However, the small size, lack of comparator, and single-centre design mean the findings cannot yet guide clinical practice; further controlled studies are needed to establish efficacy and optimal dosing.
Small retrospective single-centre case series (n=8) with no comparator, presenting observational real-world data on eravacycline safety and clinical outcomes in carbapenem-resistant infections; the authors themselves describe it as preliminary and lacking formal statistical power.
As stated by the source record.
Quoted from the source exactly as published.
This report provides preliminary observational evidence that eravacycline may be a tolerable option for treating carbapenem-resistant infections in real-world settings, particularly in burn and immunocompromised patients. However, the small size, lack of comparator, and single-centre design mean the findings cannot yet guide clinical practice; further controlled studies are needed to establish efficacy and optimal dosing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
INTRODUCTION: The purpose of this study was to describe the clinical outcomes in patients with complex infections caused by carbapenem-resistant pathogens who were treated with eravacycline (ERV) containing regimens. METHODS: A retrospective chart review was conducted at Hospital St. Georg in Leipzig, Germany, a municipal tertiary care center with specialized departments for infectious diseases and tropical medicine, septic surgery, and severe burn injuries, between 1 January 2023 and 31 December 2025. RESULTS: Eight patients (median age 38 years, 75% male) with bloodstream infections, hospital-acquired pneumonia, complex skin and soft tissue infections, and osteomyelitis were identified. Underlying conditions included severe burns, multiple myeloma, and human immunodeficiency virus (HIV) infection. The causative pathogens were carbapenemase-producing Klebsiella pneumoniae (KPC-2, NDM-1, and OXA-48) and carbapenemase-producing Acinetobacter baumannii (OXA-23, OXA-40, OXA-58, and OXA-72), including strains that expressed multiple carbapenemases. The minimum inhibitory concentrations (MICs) for ERV ranged from < 0.12 to 1.0 µg/mL. Five patients received monotherapy with ERV (100 mg twice per day (BID) intravenous (IV)), and three patients received combination therapy at the same dose along with other antimicrobial agents (ceftazidime/avibactam, sulbactam, and gentamicin). The median duration of treatment with ERV was 10 days (range 5-42 days). Clinical cure was achieved in 87.5% of patients (7/8), and all patients-with the exception of one patient with major skin and soft tissue defects and osteomyelitis-showed evidence of microbiological pathogen eradication, apart from extensive burn wounds. ERV at an increased standard dose of 100 mg BID IV was well tolerated, and no adverse events leading to treatment discontinuation were reported. CONCLUSIONS: In this small retrospective study presenting preliminary real-world observational data, ERV proved to be a safe and promising treatment option for complex infections caused by carbapenemase-producing Klebsiella pneumoniae and Acinetobacter baumannii strains, characterized by few side effects and good efficacy even outside indications specified in the approval studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.